

All communications respecting this case should identify it by number and names of parties.



**U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: BOX INTERFERENCE  
Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Telephone: (703)557-4007  
Facsimile: (703)557-8642

MAILED

FEB 28 1991

U.S. PATENT AND TRADEMARK OFFICE  
BOARD OF PATENT APPEALS  
AND INTERFERENCES

Applicants: Cabilly et al  
Serial No.: 07/205,419  
Filed: June 10, 1988  
For: RECOMBINANT IMMUNOGLOBIN  
PREPARATIONS  
Accorded Benefit of: U.S.  
S.N. 06/483,457, filed  
04/08/83, now Patent No.  
4,816,567, issued 03/28/89

The case referred to above has been forwarded to the Board of Patent Appeals and Interferences because it is adjudged to interfere with other cases hereafter specified. Attention is directed to the fact that this interference is declared pursuant to 37 CFR 1.601 et seq., effective February 11, 1985 (49 F.R. 48416. 1050 O.G. 385). The interference is designated as No. 102,572.

By direction of the Commissioner of Patents and Trademarks and as required by 35 USC 135(c), notice is hereby given the parties of the requirement of the law for filing in the Patent and Trademark Office a copy of any agreement "in connection with or in contemplation of the termination of the interference."

Sanofi/Regeneron Ex. 1014, pg 438

The cases involved in this interference are:

Junior Party

Patentees: Michael A. Boss, John H. Kenten, John S. Emtage  
and Clive R. Wood

Address: 20 Hunter Court, Huntercombe Lane North, Slough,  
Berkshire, SL1 6DS, U.K.  
24 Avery Avenue, Downley, High Wycombe, Buckinghamshire,  
U.K.  
12 Benjamin House, Amersham Hill, High Wycombe,  
Buckinghamshire, U.K.  
'Whych Wood', Buddle Hill, North Gorley, Near  
Fordingbridge, Hampshire, U.K.

Serial No.: 06/672,265, filed 11/14/84, now Patent No. 4,816,397,  
issued 03/28/89

For: MULTICHAIN POLYPEPTIDES OR PROTEINS AND PROCESSES FOR THEIR  
PRODUCTION

Assignee: Celltech Limited, Berkshire SL1 4DY, U.K., A British  
Company

Attorneys of Record: Paul N. Kokulis, Allen Kirkpatrick,  
Lloyd J. Street, George T. Mobbille, James L. Dooley,  
Alvin Gutttag, Raymond F. Lippitt, G. Lloyd Knight,  
Carl G. Love, Lawrence A. Hymo, Akin T. Davis,  
Edgar H. Martin, William K. West, Jr., Kevin E.  
Joyce, Edward M. Prince, Donald B. Deaver, David W.  
Brinkman, George M. Sirilla, William T. Bullinger,  
Donald J. Bird, Larry S. Nixon, James R. Longacre,  
Arthur R. Crawford, W. Warren Taltavull, Michael L.  
Keller, Charles R. Donohoe, Sherman O. Parrett,  
Robert A. Vanderhye, Watson T. Scott, Peter W.  
Gowdey, Michael A. Lechter, Dale S. Lazar, James T.  
Hosmer and Glenn J. Perry

Associate Attorney: None

Accorded Benefit of: None

Address: Cushman, Darby & Cushman  
Eleventh Floor  
1615 L Street, N.W.  
Washington, DC 20036

Senior Party

Applicants: Shmuel Cabilly, Herbert L. Heyneker,  
William E. Holmes, Arthur D. Riggs and  
Ronald B. Wetzal

Address: 2038 S. Peck, Monrovia, CA 91016  
2621 Easton Drive, Burlingame, CA 94010  
29 Eastlake, Pacifica, CA 94044  
4852 St. Andres Avenue, La Verne, CA 91750  
76 Melrose Avenue, San Francisco, CA 94131

Serial No.: 07/205,419, filed 06/10/88

For: RECOMBINANT IMMUNOGLOBULIN PREPARATIONS

Assignee: Genentech, Inc., South San Francisco, CA, A California  
Corporation

Attorneys of Record: Walter H. Dreger, Thomas D. Kiley,  
Kate H. Murashige, Max D. Hensley and Janet E. Hasak

Associate Attorneys: None

Accorded Benefit of: U.S. S.N. 06/483,457, filed 04/08/83, now  
Patent No. 4,816,567, issued 03/28/89

Address: Max D. Hensley  
Genentech, Inc.  
460 Point San Bruno Blvd.  
So. San Francisco, CA 94080

Count 1

A process for producing an Ig molecule or an immunologically functional Ig fragment comprising at least the variable domains of the Ig heavy and light chains, in a single host cell, comprising the steps of:


(i) transforming said single host cell with a first DNA sequence encoding at least the variable domain of the Ig heavy chain and a second DNA sequence encoding at least the variable domain of the Ig light chain, and

(ii) independently expressing said first DNA sequence and said second DNA sequence so that said Ig heavy and light chains are produced as separate molecules in said transformed single host cell.

The claims of the parties which correspond to this count are:

Boss et al: Claims 1-18.

Cabilly et al: Claims 101-120.

  
Mary F. Downey  
Examiner-in-Chief  
(703) 557-4003

MFD/raj